Interventions for adherence with oral chemotherapy in hematological malignancies: A systematic review

Research in Social and Administrative Pharmacy

Volumn 11, Issue 3, 2015, Pages 303-314

  Kavookjian, Jan ^a   Wittayanukorn, Saranrat ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Adherence; Hematological malignancies; Intervention(s); Oral chemotherapy; Outcome(s)

Indexed keywords

ANTINEOPLASTIC AGENT;

HEMATOLOGIC NEOPLASMS; HUMAN; MEDICATION COMPLIANCE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC;

EID: 84927929932     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2014.08.006     Document Type: Review

References (41)

1. The Leukemia & Lymphoma Society. Facts 2012. Accessed 08.06.13. http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.pdf.
2. Howlader N., Noone A.M., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) 2011, Accessed 08.06.13. http://seer.cancer.gov/csr/1975_2009_pops09/.
3. American Cancer Society. Cancer facts & figures2012. Accessed 08.06.13. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
4. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007, 64(9 suppl 5):S4-S7.
5. Partridge A.H., Avorn J., Wang P.S., et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002, 94(9):652-661.
6. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59(1):56-66.
7. Weingart S.N., Brown E., Bach P.B., et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 2008, 6(suppl 3):S1-S14.
8. Blecher C., Barefoot J., Davis D., et al. A team approach toward promoting patient adherence to oral chemotherapy protocols. Oncol Nurs Forum 2008, 35(3):537. abstr 2985.
9. Lebovits A.H., Strain J.J., Schleifer S.J., et al. Patient noncompliance with self-administered chemotherapy. Cancer 1990, 65(1):17-22.
10. Liu G., Franssen E., Fitch M.I., et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15(1):110-115.
11. Viele C.S. Managing oral chemotherapy: the healthcare practitioner's role. Am J Health Syst Pharm 2007, 64(9 suppl 5):S25-S32.
12. Haynes R.B., Ackloo E., Sahota N., et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, 2:CD000011.
13. Sabaté E. Adherence to Long-term Therapies - Evidence for Action 2003, World Health Organization, Accessed 08.06.13. http://apps.who.int/medicinedocs/pdf/s4883e/s4883e.pdf.
14. Escalada P., Griffiths P. Do people with cancer comply with oral chemotherapy treatments?. Br J Community Nurs 2006, 11(12):532-536.
15. Gater A., Heron L., Abetz-Webb L., et al. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res 2012, 36(7):817-825.
16. Breccia M., Efficace F., Alimena G. Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Leuk Res 2012, 36(7):804-805.
17. O'Brien S., Berman E., Moore J.O., et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011, 9(suppl 2):S1-S25.
18. Marin D., Bazeos A., Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28(14):2381-2388.
19. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353(5):487-497.
20. Jabbour E., Saglio G., Hughes T.P., et al. Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer 2012, 118(5):1181-1191.
21. Font R., Espinas J.A., Gil-Gil M., et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 2012, 107(8):1249-1256.
22. Simons S., Ringsdorf S., Braun M., et al. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 2011, 19(7):1009-1018.
23. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 2011, [Updated March 2011], The Cochrane Collaboration.
24. Higgins J.P.T., Altman D.G., Sterne J.E. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 2011, [Updated March 2011], The Cochrane Collaboration. S. Green (Ed.).
25. Doti C., Stemmelin G., Shanley C., et al. Cytogenetic response in relation to the adherence to treatment with Imatinib Mesylate: a case control study. Blood 2007, 110(11):4553.
26. Klein C.E., Kastrissios H., Miller A.A., et al. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 2006, 57(2):199-206.
27. Levine A.M., Richardson J.L., Marks G., et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987, 5(9):1469-1476.
28. Moon J.H., Sohn S.K., Kim S.N., et al. Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol 2012, 29(2):1179-1185.
29. Richardson J.L., Marks G., Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988, 6(11):1746-1752.
30. Richardson J.L., Shelton D.R., Krailo M., et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 1990, 8(2):356-364.
31. Krueger K.P., Berger B.A., Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005, 22(4):319-362.
32. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23(8):1296-1310.
33. Ran M.S., Xiang M.Z., Chan C.L., et al. Effectiveness of psychoeducational intervention for rural Chinese families experiencing schizophrenia-a randomised controlled trial. Soc Psychiatry Psychiatr Epidemiol 2003, 38(2):69-75.
34. Williams A., Manias E., Walker R. Interventions to improve medication adherence in people with multiple chronic conditions: a systematic review. J Adv Nurs 2008, 63(2):132-143.
35. Zeppetella G. How do terminally ill patients at home take their medication?. J Palliat Med 1999, 13(6):469-475.
36. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408-2417.
37. Noens L., van Lierde M.A., De Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113(22):5401-5411.
38. Leger F., Loos W.J., Fourcade J., et al. Factors affectingpharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer 2004, 90(2):343-347.
39. Spoelstra S.L., Given C.W. Assessment and measurement of adherence to oral atineoplastic agents. Semin Oncol Nurs 2011, 2:116-132.
40. Col N., Fanale J.E., Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990, 150(4):841-845.
41. Schneider S.M., Hess K., Gosselin T. Interventions to promote adherence with oral agents. Semin Oncol Nurs 2011, 2:133-141.